Bristol-Myers Bets Nearly $2B on Nektar for an Immunotherapy Boost – Xconomy
Xconomy |
Bristol-Myers Bets Nearly $2B on Nektar for an Immunotherapy Boost
Xconomy When it comes to spending cash on potential combinations for its cancer immunotherapy drugs, Bristol-Myers Squibb (NYSE: BMY) isn't afraid of the b-word: billions. The New York-based pharma firm is paying Nektar Therapeutics (NASDAQ: NKTR) of San … Bristol, needing a cancer immunotherapy boost, pays shockingly steep price for Nektar drug Why Bristol-Myers Squibb just made a $1.85 billion bet on a cancer drug Record-smashing $3.6 billion deal propels SF drug company in cancer immunotherapy pack |
